Sequencing of agents in castration-resistant prostate cancer
Until 2010, docetaxel was the only agent with proven survival benefit for castration-resistant prostate cancer. The development of cabazitaxel, abiraterone acetate, enzalutamide, radium-223, and sipuleucel-T has increased the number of treatment options. Because these agents were developed concurren...
Saved in:
| Published in | The lancet oncology Vol. 16; no. 6; pp. e279 - e292 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.06.2015
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Until 2010, docetaxel was the only agent with proven survival benefit for castration-resistant prostate cancer. The development of cabazitaxel, abiraterone acetate, enzalutamide, radium-223, and sipuleucel-T has increased the number of treatment options. Because these agents were developed concurrently within a short period of time, prospective data on their sequential use efficacy are scarce. The challenge now is to reach a consensus on the best way to sequence effective treatments, ideally by the use of an approach specific to patient subgroups. However, the absence of robust surrogates of survival and the lack of predictive biomarkers makes data for the sequential use of these agents difficult to obtain and interpret. |
|---|---|
| AbstractList | Summary Until 2010, docetaxel was the only agent with proven survival benefit for castration-resistant prostate cancer. The development of cabazitaxel, abiraterone acetate, enzalutamide, radium-223, and sipuleucel-T has increased the number of treatment options. Because these agents were developed concurrently within a short period of time, prospective data on their sequential use efficacy are scarce. The challenge now is to reach a consensus on the best way to sequence effective treatments, ideally by the use of an approach specific to patient subgroups. However, the absence of robust surrogates of survival and the lack of predictive biomarkers makes data for the sequential use of these agents difficult to obtain and interpret. Until 2010, docetaxel was the only agent with proven survival benefit for castration-resistant prostate cancer. The development of cabazitaxel, abiraterone acetate, enzalutamide, radium-223, and sipuleucel-T has increased the number of treatment options. Because these agents were developed concurrently within a short period of time, prospective data on their sequential use efficacy are scarce. The challenge now is to reach a consensus on the best way to sequence effective treatments, ideally by the use of an approach specific to patient subgroups. However, the absence of robust surrogates of survival and the lack of predictive biomarkers makes data for the sequential use of these agents difficult to obtain and interpret. |
| Author | Lorente, David de Bono, Johann S Attard, Gerhardt Perez-Lopez, Raquel Mateo, Joaquin |
| Author_xml | – sequence: 1 givenname: David surname: Lorente fullname: Lorente, David organization: Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK – sequence: 2 givenname: Joaquin surname: Mateo fullname: Mateo, Joaquin organization: Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK – sequence: 3 givenname: Raquel surname: Perez-Lopez fullname: Perez-Lopez, Raquel organization: Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK – sequence: 4 givenname: Johann S surname: de Bono fullname: de Bono, Johann S organization: Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK – sequence: 5 givenname: Gerhardt surname: Attard fullname: Attard, Gerhardt email: gerhardt.attard@icr.ac.uk organization: Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26065613$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkV1LHTEQhoNY6ld_gmWhN3qxdbL52CzWSpHaCoIXttchJrMS3ZO1SY7gv2_OriIcKPYqQ_LOM2_e2SGbYQxIyD6FzxSoPLqmvIW6AS4OqDhsARir6QbZLte8FlypzameJVtkJ6U7ANpSEO_JViNBCknZNvlyjX-WGKwPt9XYV-YWQ06VD5U1KUeT_RjqiMmnbEKuHuJYiozlNViMe-Rdb4aEH57PXfL7_Puvs5_15dWPi7Nvl7UVUuXatuqGomuc6pmjtmPOFCNWWVBKmo5bYNDIIuic7EA2XHXYsp4bcIyD6NkuOZi5ZX5xm7Je-GRxGEzAcZk0bYG10AFvivTTmvRuXMZQ3GkqFROqwFVRfXxWLW8W6PRD9AsTn_RLLkVwPAts-XGK2Gvr85RGCcUPmoJebUFPW9CriDUVetqCpqVbrHW_DHir73TuwxLmo8eok_VlOeh8RJu1G_2bhK9rBDv44K0Z7vEJ02sWOjUaZsiKQcVEWAFO_g34DwN_AQztxCU |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1016_j_ajur_2018_11_005 crossref_primary_10_1038_s41467_018_08152_3 crossref_primary_10_1007_s00345_019_02658_1 crossref_primary_10_1016_j_urolonc_2018_08_002 crossref_primary_10_1007_s12094_017_1785_0 crossref_primary_10_1007_s40265_018_1029_9 crossref_primary_10_1016_j_ejca_2016_11_027 crossref_primary_10_1016_j_critrevonc_2020_103185 crossref_primary_10_3390_cancers12040995 crossref_primary_10_1021_jacs_8b10021 crossref_primary_10_1634_theoncologist_2016_0161 crossref_primary_10_1158_1078_0432_CCR_23_3083 crossref_primary_10_1155_2022_8726662 crossref_primary_10_1177_0300891619851376 crossref_primary_10_3390_cancers14071792 crossref_primary_10_2217_fon_2018_0113 crossref_primary_10_1093_annonc_mdx155 crossref_primary_10_1016_j_urolonc_2017_01_020 crossref_primary_10_1093_aje_kwaa190 crossref_primary_10_1038_s41391_021_00326_3 crossref_primary_10_1002_pros_23246 crossref_primary_10_1007_s40291_016_0196_1 crossref_primary_10_1053_j_seminoncol_2017_10_005 crossref_primary_10_1016_j_acuroe_2018_11_004 crossref_primary_10_1111_iju_13134 crossref_primary_10_3769_radioisotopes_66_695 crossref_primary_10_1016_j_remn_2018_11_002 crossref_primary_10_1016_j_biomaterials_2016_05_015 crossref_primary_10_3390_cancers12010008 crossref_primary_10_1016_j_bulcan_2017_02_002 crossref_primary_10_1016_j_eururo_2018_03_028 crossref_primary_10_1016_j_mce_2017_08_020 crossref_primary_10_1016_j_acuro_2018_03_004 crossref_primary_10_3348_jksr_2023_0060 crossref_primary_10_1002_pros_24069 crossref_primary_10_1146_annurev_bioeng_062117_120931 crossref_primary_10_1016_j_ctrv_2018_05_011 crossref_primary_10_1016_j_euf_2016_09_005 crossref_primary_10_1016_j_acuro_2017_05_005 crossref_primary_10_1007_s10637_020_00934_1 crossref_primary_10_1016_j_jconrel_2020_04_003 crossref_primary_10_1007_s12032_017_1014_2 crossref_primary_10_1101_cshperspect_a030635 crossref_primary_10_1038_s41419_023_05818_9 crossref_primary_10_18632_oncotarget_12554 crossref_primary_10_1016_j_clgc_2017_06_004 crossref_primary_10_1016_j_neo_2019_06_002 crossref_primary_10_1016_j_critrevonc_2016_04_014 crossref_primary_10_1016_j_acuroe_2018_03_003 crossref_primary_10_1200_JGO_18_00009 crossref_primary_10_1016_j_eururo_2018_02_013 crossref_primary_10_3390_biomedicines9091247 crossref_primary_10_1007_s10637_016_0385_0 crossref_primary_10_1158_0008_5472_CAN_22_1533 crossref_primary_10_1111_bju_14152 crossref_primary_10_1002_advs_202407662 crossref_primary_10_3390_biom11040492 crossref_primary_10_1016_j_ctrv_2016_06_005 crossref_primary_10_1080_14656566_2017_1323875 crossref_primary_10_3389_fphar_2017_00836 crossref_primary_10_1111_cas_15984 crossref_primary_10_3390_v15040901 crossref_primary_10_1038_aps_2017_36 crossref_primary_10_1111_iju_13346 crossref_primary_10_4329_wjr_v8_i10_816 crossref_primary_10_1016_j_critrevonc_2016_02_013 crossref_primary_10_1016_j_urology_2017_04_062 crossref_primary_10_3390_biomedicines10123262 crossref_primary_10_1093_annonc_mdx348 crossref_primary_10_1158_1078_0432_CCR_16_1355 crossref_primary_10_1007_s11523_017_0500_y crossref_primary_10_1002_pros_24706 crossref_primary_10_1016_j_eururo_2019_08_034 crossref_primary_10_1007_s40487_021_00181_1 crossref_primary_10_1111_imj_14262 crossref_primary_10_1021_acs_analchem_7b03568 crossref_primary_10_1111_cas_13751 crossref_primary_10_1177_1078155216674354 crossref_primary_10_1016_j_ejca_2021_09_034 crossref_primary_10_18632_oncotarget_17980 crossref_primary_10_1016_j_euros_2024_06_010 crossref_primary_10_1007_s11523_020_00720_2 crossref_primary_10_1002_iub_2665 crossref_primary_10_1002_pros_23064 crossref_primary_10_1111_bju_13764 crossref_primary_10_1016_j_eururo_2015_08_017 crossref_primary_10_1111_bju_14576 crossref_primary_10_1016_j_euros_2022_08_018 crossref_primary_10_1016_j_eururo_2016_08_037 crossref_primary_10_1016_j_clgc_2017_12_004 crossref_primary_10_1093_annonc_mdv282 crossref_primary_10_1016_j_prnil_2020_09_001 crossref_primary_10_20960_revcancer_00047 crossref_primary_10_1038_nrd_2016_120 crossref_primary_10_1038_s41598_020_80519_3 crossref_primary_10_1016_j_eururo_2017_08_012 crossref_primary_10_1111_jcmm_13475 crossref_primary_10_18632_oncotarget_28015 crossref_primary_10_3390_cancers13184522 crossref_primary_10_1038_s41419_018_0866_5 crossref_primary_10_3390_biomedicines9040339 crossref_primary_10_1177_1758834017719215 crossref_primary_10_1016_j_bbagen_2017_12_001 crossref_primary_10_1186_s12885_018_4527_y crossref_primary_10_15406_jcpcr_2017_08_00295 crossref_primary_10_1016_j_ucl_2018_03_016 crossref_primary_10_3390_ijms20123100 crossref_primary_10_1038_srep36721 crossref_primary_10_12677_ACM_2021_1111815 crossref_primary_10_1016_j_remnie_2019_02_001 crossref_primary_10_1016_j_drup_2021_100761 crossref_primary_10_1016_j_juro_2018_01_069 crossref_primary_10_1007_s00120_018_0679_2 crossref_primary_10_1016_j_tips_2016_03_003 crossref_primary_10_1038_nrurol_2016_205 |
| Cites_doi | 10.1200/JCO.2014.55.3487 10.1093/annonc/mdt138 10.1016/j.clgc.2014.06.007 10.1200/JCO.2012.45.0494 10.1016/S0140-6736(10)61389-X 10.1056/NEJMoa1405095 10.1093/annonc/mds119 10.1093/annonc/mdn544 10.1056/NEJMoa1213755 10.1016/j.urology.2013.01.061 10.1200/JCO.2005.04.8207 10.1007/s00262-012-1317-2 10.1158/1078-0432.CCR-08-0872 10.1002/pros.22872 10.1016/j.mri.2009.12.008 10.1158/0008-5472.CAN-08-3667 10.1056/NEJMoa1207506 10.1016/S1470-2045(12)70379-0 10.1016/j.eururo.2014.10.004 10.1016/j.eururo.2013.06.042 10.1200/jco.2013.31.6_suppl.6 10.1002/cncr.23864 10.1056/NEJMoa1315815 10.1002/ijc.29231 10.1093/annonc/mdt581 10.1158/2159-8290.CD-13-0226 10.1016/S0140-6736(10)60172-9 10.1126/science.97.2529.541 10.1056/NEJMoa1209096 10.1158/0008-5472.CAN-11-3892 10.1093/annonc/mdt194 10.1158/1078-0432.CCR-12-2910 10.1158/0008-5472.CAN-11-1417 10.1158/1078-0432.CCR-08-0596 10.1016/j.eururo.2014.06.042 10.1016/S0140-6736(11)61226-9 10.1093/jnci/djk178 10.1200/JCO.2012.45.4595 10.1158/2159-8290.CD-13-0142 10.1200/JCO.2005.04.5252 10.1016/S1470-2045(14)70189-5 10.1016/j.eururo.2014.02.014 10.1093/annonc/mdu587 10.1016/S1470-2045(14)71205-7 10.1056/NEJMoa1001294 10.1016/j.eururo.2014.06.045 10.1016/j.cell.2013.11.012 10.1158/1078-0432.CCR-14-1961 10.1016/j.ejca.2013.08.020 10.1200/jco.2014.32.18_suppl.lba2 10.1111/bju.12845 10.1200/JCO.2007.12.4008 10.1158/1078-0432.CCR-12-3146 10.1158/0008-5472.CAN-11-3980 10.1016/j.eururo.2014.01.018 10.1158/1078-0432.CCR-14-1220 10.1126/scitranslmed.3009448 10.1016/j.eururo.2013.11.044 10.1016/j.clgc.2014.03.010 10.1002/cncr.28518 10.1056/NEJMoa041318 10.1200/JCO.2005.01.529 10.1093/annonc/mdt136 10.1038/bjc.2013.446 10.1038/pcan.2013.2 10.1093/annonc/mdn288 10.1158/1078-0432.CCR-07-0944 10.1111/j.1742-1241.2011.02799.x 10.1200/JCO.2007.12.4487 10.1038/ncomms6548 10.1016/j.eururo.2013.08.007 10.1056/NEJMoa040720 10.1038/76287 10.1016/j.eururo.2014.10.027 10.1002/cncr.24429 |
| ContentType | Journal Article |
| Copyright | 2015 Elsevier Ltd Elsevier Ltd Copyright © 2015 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jun 2015 |
| Copyright_xml | – notice: 2015 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2015 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jun 2015 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1016/S1470-2045(15)70033-1 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Pharma and Biotech Premium PRO MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | e292 |
| ExternalDocumentID | 3697319961 26065613 10_1016_S1470_2045_15_70033_1 S1470204515700331 1_s2_0_S1470204515700331 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Prostate Cancer UK grantid: PG12-49 – fundername: Medical Research Council – fundername: Cancer Research UK grantid: 13239 |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c568t-c78b1ed2d8f3d1c93da171c8c0886a94c03026ed29d69062489e73f4a0d3405f3 |
| IEDL.DBID | 7X7 |
| ISSN | 1470-2045 |
| IngestDate | Fri Jul 11 06:17:59 EDT 2025 Fri Jul 25 08:08:10 EDT 2025 Mon Jul 21 05:57:36 EDT 2025 Tue Jul 01 04:04:47 EDT 2025 Thu Apr 24 22:58:58 EDT 2025 Fri Feb 23 02:18:58 EST 2024 Sun Feb 23 10:18:55 EST 2025 Tue Aug 26 19:22:28 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | Copyright © 2015 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c568t-c78b1ed2d8f3d1c93da171c8c0886a94c03026ed29d69062489e73f4a0d3405f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| PMID | 26065613 |
| PQID | 1683584898 |
| PQPubID | 46089 |
| ParticipantIDs | proquest_miscellaneous_1703709042 proquest_journals_1683584898 pubmed_primary_26065613 crossref_citationtrail_10_1016_S1470_2045_15_70033_1 crossref_primary_10_1016_S1470_2045_15_70033_1 elsevier_sciencedirect_doi_10_1016_S1470_2045_15_70033_1 elsevier_clinicalkeyesjournals_1_s2_0_S1470204515700331 elsevier_clinicalkey_doi_10_1016_S1470_2045_15_70033_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2015-06-01 |
| PublicationDateYYYYMMDD | 2015-06-01 |
| PublicationDate_xml | – month: 06 year: 2015 text: 2015-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2015 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Sweeney, Chen, Carducci (bib3) 2014; 32 Kwon, Drake, Scher (bib26) 2014; 15 Wirth, Tammela, Cicalese (bib56) 2015; 67 de Bono, Oudard, Ozguroglu (bib7) 2010; 376 Goudarzi, Kishimoto, Komatsu (bib53) 2010; 28 Chen, Sowalsky, Gao (bib66) 2014; 21 Huggins (bib2) 1943; 97 Sheikh, Petrylak, Kantoff (bib71) 2013; 62 Hoffman-Censits, Kelly (bib22) 2013; 19 Schellhammer, Chodak, Whitmore, Sims, Frohlich, Kantoff (bib25) 2013; 81 Ferlay, Soerjomataram, Ervik (bib1) Wissing, Coenen, van den Berg (bib40) 2015; 136 Omlin, Pezaro, Zaidi (bib44) 2013; 109 Nelson, Love, Chin (bib57) 2008; 113 Oudard, Kramer, Caffo (bib43) 2015; 115 Bianchini, Lorente, Rodriguez-Vida (bib34) 2013; 50 Sella, Sella, Peer (bib39) 2014; 12 Antonarakis, Lu, Wang (bib59) 2014; 371 Scher, Beer, Higano (bib23) 2010; 375 Scher, Halabi, Tannock (bib74) 2008; 26 Scher, Heller, Molina (bib78) 2015; 33 Berthold, Pond, Roessner, de Wit, Eisenberger, Tannock (bib67) 2008; 14 Aggarwal, Harris, Formaker (bib29) 2014; 12 Ryan, Molina, Li (bib69) 2013; 31 Lorente, Mateo, Templeton (bib70) 2015; 26 Kantoff, Higano, Shore (bib14) 2010; 363 Joseph, Lu, Qian (bib65) 2013; 3 Scher, Fizazi, Saad (bib10) 2012; 367 Hu, Lu, Mostaghel (bib72) 2012; 72 Beer, Armstrong, Rathkopf (bib11) 2014; 371 Korpal, Korn, Gao (bib73) 2013; 3 Berthold, Pond, de Wit, Eisenberger, Tannock (bib16) 2008; 19 Galletti, Matov, Beltran (bib62) 2014; 5 Badrising, van der Noort, van Oort (bib36) 2013; 120 Azad, Eigl, Murray, Kollmannsberger, Chi (bib37) 2015; 67 Mason, Sydes, Gholm (bib55) 2007; 99 Smith, Saad, Coleman (bib52) 2012; 379 Venkitaraman, Lorente, Murthy (bib45) 2014; 67 Smith, Kabbinavar, Saad (bib54) 2005; 23 Attard, de Bono, Li (bib60) 2015; 21 Richards, Lim, Hay (bib21) 2012; 72 Small, Schellhammer, Higano (bib12) 2006; 24 Higano, Schellhammer, Small (bib13) 2009; 115 Montgomery, Kheoh, Molina (bib49) 2015; 67 Smith, Smith, Sweeney (bib75) 2013; 31 Van Soest, de Morrée, Shen, Tannock, Eisenberger, de Wit (bib68) 2013; 66 Mita, Denis, Rowinsky (bib20) 2009; 15 Azad, Leibowitz-Amit, Eigl (bib30) 2014; 74 Schweizer, Zhou, Wang (bib28) 2014; 66 Mezynski, Pezaro, Bianchini (bib27) 2012; 23 Pezaro, Omlin, Altavilla (bib38) 2014; 66 Parker, Nilsson, Heinrich (bib15) 2013; 369 Berthold, Pond, Soban, de Wit, Eisenberger, Tannock (bib4) 2008; 26 Miller, Moul, Gleave (bib58) 2013; 16 Carreira, Romanel, Goodall (bib48) 2014; 6 Scher, Fizazi, Saad (bib50) 2013; 31 Al Nakouzi, Le Moulec, Albigès (bib41) 2014; 66 Berry, Moinpour, Jiang (bib17) 2006; 24 Leibowitz-Amit, Templeton, Omlin (bib64) 2014; 25 Noonan, North, Bitting, Armstrong, Ellard, Chi (bib32) 2013; 24 Ryan, Smith, de Bono (bib9) 2013; 368 Fizazi, Scher, Molina (bib8) 2012; 13 Arora, Schenkein, Murali (bib46) 2013; 155 Tannock, de Wit, Berry (bib6) 2004; 351 Thomsen, Røder, Rathenborg, Brasso, Borre, Iversen (bib35) 2013 de Bono, Scher, Montgomery (bib76) 2008; 14 Olmos, Arkenau, Ang (bib77) 2009; 20 Vrignaud, Sémiond, Lejeune (bib18) 2013; 19 Loriot, Bianchini, Ileana (bib31) 2013; 24 Schrader, Boegemann, Ohlmann (bib33) 2014; 65 Zhao, Malloy, Krishnan (bib47) 2000; 6 Bahl, Oudard, Tombal (bib19) 2013; 24 Ryan, Smith, Fizazi (bib24) 2015; 16 Ferraldeschi, Nava Rodrigues, Riisnaes (bib63) 2014; 67 Attard, Swennenhuis, Olmos (bib61) 2009; 69 Kirby, Hirst, Crawford (bib51) 2011; 65 Darshan, Loftus, Thadani-Mulero (bib42) 2011; 71 Petrylak, Tangen, Hussain (bib5) 2004; 351 Ryan (10.1016/S1470-2045(15)70033-1_bib9) 2013; 368 Smith (10.1016/S1470-2045(15)70033-1_bib75) 2013; 31 Mita (10.1016/S1470-2045(15)70033-1_bib20) 2009; 15 Attard (10.1016/S1470-2045(15)70033-1_bib60) 2015; 21 Van Soest (10.1016/S1470-2045(15)70033-1_bib68) 2013; 66 Mezynski (10.1016/S1470-2045(15)70033-1_bib27) 2012; 23 Arora (10.1016/S1470-2045(15)70033-1_bib46) 2013; 155 Parker (10.1016/S1470-2045(15)70033-1_bib15) 2013; 369 Loriot (10.1016/S1470-2045(15)70033-1_bib31) 2013; 24 Ryan (10.1016/S1470-2045(15)70033-1_bib69) 2013; 31 Fizazi (10.1016/S1470-2045(15)70033-1_bib8) 2012; 13 Omlin (10.1016/S1470-2045(15)70033-1_bib44) 2013; 109 Olmos (10.1016/S1470-2045(15)70033-1_bib77) 2009; 20 Kantoff (10.1016/S1470-2045(15)70033-1_bib14) 2010; 363 Higano (10.1016/S1470-2045(15)70033-1_bib13) 2009; 115 Thomsen (10.1016/S1470-2045(15)70033-1_bib35) 2013 Venkitaraman (10.1016/S1470-2045(15)70033-1_bib45) 2014; 67 Schweizer (10.1016/S1470-2045(15)70033-1_bib28) 2014; 66 Tannock (10.1016/S1470-2045(15)70033-1_bib6) 2004; 351 Montgomery (10.1016/S1470-2045(15)70033-1_bib49) 2015; 67 Kwon (10.1016/S1470-2045(15)70033-1_bib26) 2014; 15 Huggins (10.1016/S1470-2045(15)70033-1_bib2) 1943; 97 Bianchini (10.1016/S1470-2045(15)70033-1_bib34) 2013; 50 Small (10.1016/S1470-2045(15)70033-1_bib12) 2006; 24 Lorente (10.1016/S1470-2045(15)70033-1_bib70) 2015; 26 Berry (10.1016/S1470-2045(15)70033-1_bib17) 2006; 24 Vrignaud (10.1016/S1470-2045(15)70033-1_bib18) 2013; 19 Wissing (10.1016/S1470-2045(15)70033-1_bib40) 2015; 136 Scher (10.1016/S1470-2045(15)70033-1_bib74) 2008; 26 Smith (10.1016/S1470-2045(15)70033-1_bib52) 2012; 379 Goudarzi (10.1016/S1470-2045(15)70033-1_bib53) 2010; 28 Sheikh (10.1016/S1470-2045(15)70033-1_bib71) 2013; 62 Ferraldeschi (10.1016/S1470-2045(15)70033-1_bib63) 2014; 67 Azad (10.1016/S1470-2045(15)70033-1_bib37) 2015; 67 Badrising (10.1016/S1470-2045(15)70033-1_bib36) 2013; 120 Leibowitz-Amit (10.1016/S1470-2045(15)70033-1_bib64) 2014; 25 Antonarakis (10.1016/S1470-2045(15)70033-1_bib59) 2014; 371 Korpal (10.1016/S1470-2045(15)70033-1_bib73) 2013; 3 Pezaro (10.1016/S1470-2045(15)70033-1_bib38) 2014; 66 Aggarwal (10.1016/S1470-2045(15)70033-1_bib29) 2014; 12 Schrader (10.1016/S1470-2045(15)70033-1_bib33) 2014; 65 Scher (10.1016/S1470-2045(15)70033-1_bib23) 2010; 375 Smith (10.1016/S1470-2045(15)70033-1_bib54) 2005; 23 Miller (10.1016/S1470-2045(15)70033-1_bib58) 2013; 16 Scher (10.1016/S1470-2045(15)70033-1_bib50) 2013; 31 de Bono (10.1016/S1470-2045(15)70033-1_bib76) 2008; 14 Ferlay (10.1016/S1470-2045(15)70033-1_bib1) Sweeney (10.1016/S1470-2045(15)70033-1_bib3) 2014; 32 Petrylak (10.1016/S1470-2045(15)70033-1_bib5) 2004; 351 Joseph (10.1016/S1470-2045(15)70033-1_bib65) 2013; 3 Oudard (10.1016/S1470-2045(15)70033-1_bib43) 2015; 115 Attard (10.1016/S1470-2045(15)70033-1_bib61) 2009; 69 Scher (10.1016/S1470-2045(15)70033-1_bib78) 2015; 33 Kirby (10.1016/S1470-2045(15)70033-1_bib51) 2011; 65 Azad (10.1016/S1470-2045(15)70033-1_bib30) 2014; 74 Darshan (10.1016/S1470-2045(15)70033-1_bib42) 2011; 71 Scher (10.1016/S1470-2045(15)70033-1_bib10) 2012; 367 Carreira (10.1016/S1470-2045(15)70033-1_bib48) 2014; 6 Nelson (10.1016/S1470-2045(15)70033-1_bib57) 2008; 113 Hu (10.1016/S1470-2045(15)70033-1_bib72) 2012; 72 Berthold (10.1016/S1470-2045(15)70033-1_bib67) 2008; 14 Schellhammer (10.1016/S1470-2045(15)70033-1_bib25) 2013; 81 Mason (10.1016/S1470-2045(15)70033-1_bib55) 2007; 99 Hoffman-Censits (10.1016/S1470-2045(15)70033-1_bib22) 2013; 19 Wirth (10.1016/S1470-2045(15)70033-1_bib56) 2015; 67 Galletti (10.1016/S1470-2045(15)70033-1_bib62) 2014; 5 Berthold (10.1016/S1470-2045(15)70033-1_bib4) 2008; 26 Zhao (10.1016/S1470-2045(15)70033-1_bib47) 2000; 6 Ryan (10.1016/S1470-2045(15)70033-1_bib24) 2015; 16 Al Nakouzi (10.1016/S1470-2045(15)70033-1_bib41) 2014; 66 Berthold (10.1016/S1470-2045(15)70033-1_bib16) 2008; 19 Chen (10.1016/S1470-2045(15)70033-1_bib66) 2014; 21 Noonan (10.1016/S1470-2045(15)70033-1_bib32) 2013; 24 Beer (10.1016/S1470-2045(15)70033-1_bib11) 2014; 371 Bahl (10.1016/S1470-2045(15)70033-1_bib19) 2013; 24 Richards (10.1016/S1470-2045(15)70033-1_bib21) 2012; 72 Sella (10.1016/S1470-2045(15)70033-1_bib39) 2014; 12 de Bono (10.1016/S1470-2045(15)70033-1_bib7) 2010; 376 |
| References_xml | – volume: 16 start-page: 187 year: 2013 end-page: 192 ident: bib58 article-title: Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer publication-title: Prostate Cancer Prostatic Dis – volume: 3 start-page: 1030 year: 2013 end-page: 1043 ident: bib73 article-title: An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) publication-title: Cancer Discov – volume: 67 start-page: 23 year: 2015 end-page: 29 ident: bib37 article-title: Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients publication-title: Eur Urol – volume: 367 start-page: 1187 year: 2012 end-page: 1197 ident: bib10 article-title: Increased survival with enzalutamide in prostate cancer after chemotherapy publication-title: N Engl J Med – volume: 368 start-page: 138 year: 2013 end-page: 148 ident: bib9 article-title: Abiraterone in metastatic prostate cancer without previous chemotherapy publication-title: N Engl J Med – volume: 15 start-page: 700 year: 2014 end-page: 712 ident: bib26 article-title: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial publication-title: Lancet Oncol – volume: 6 start-page: 254ra125 year: 2014 ident: bib48 article-title: Tumor clone dynamics in lethal prostate cancer publication-title: Sci Transl Med – volume: 120 start-page: 968 year: 2013 end-page: 975 ident: bib36 article-title: Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment publication-title: Cancer – volume: 24 start-page: 1802 year: 2013 end-page: 1807 ident: bib32 article-title: Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide publication-title: Ann Oncol – volume: 363 start-page: 411 year: 2010 end-page: 422 ident: bib14 article-title: Sipuleucel-T immunotherapy for castration-resistant prostate cancer publication-title: N Engl J Med – volume: 115 start-page: 744 year: 2015 end-page: 752 ident: bib43 article-title: Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer publication-title: BJU Int – volume: 23 start-page: 2918 year: 2005 end-page: 2925 ident: bib54 article-title: Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer publication-title: J Clin Oncol – volume: 26 start-page: 1148 year: 2008 end-page: 1159 ident: bib74 article-title: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group publication-title: J Clin Oncol – volume: 65 start-page: 1180 year: 2011 end-page: 1192 ident: bib51 article-title: Characterising the castration-resistant prostate cancer population: a systematic review publication-title: Int J Clin Pract – volume: 5 start-page: 5548 year: 2014 ident: bib62 article-title: ERG induces taxane resistance in castration-resistant prostate cancer publication-title: Nat Commun – volume: 351 start-page: 1513 year: 2004 end-page: 1520 ident: bib5 article-title: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer publication-title: N Engl J Med – volume: 12 start-page: 428 year: 2014 end-page: 432 ident: bib39 article-title: Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer publication-title: Clin Genitourin Cancer – volume: 62 start-page: 137 year: 2013 end-page: 147 ident: bib71 article-title: Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer publication-title: Cancer Immunol Immunother – volume: 351 start-page: 1502 year: 2004 end-page: 1512 ident: bib6 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer publication-title: N Engl J Med – volume: 97 start-page: 541 year: 1943 end-page: 544 ident: bib2 article-title: Endocrine control of prostate cancer publication-title: Science – volume: 379 start-page: 39 year: 2012 end-page: 46 ident: bib52 article-title: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial publication-title: Lancet – volume: 369 start-page: 213 year: 2013 end-page: 223 ident: bib15 article-title: Alpha emitter radium-223 and survival in metastatic prostate cancer publication-title: N Engl J Med – volume: 23 start-page: 2943 year: 2012 end-page: 2947 ident: bib27 article-title: Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? publication-title: Ann Oncol – volume: 24 start-page: 2828 year: 2006 end-page: 2835 ident: bib17 article-title: Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone publication-title: J Clin Oncol – volume: 74 start-page: 1544 year: 2014 end-page: 1550 ident: bib30 article-title: A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer publication-title: Prostate – volume: 66 start-page: 646 year: 2014 end-page: 652 ident: bib28 article-title: The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer publication-title: Eur Urol – volume: 15 start-page: 723 year: 2009 end-page: 730 ident: bib20 article-title: Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors publication-title: Clin Cancer Res – volume: 16 start-page: 152 year: 2015 end-page: 160 ident: bib24 article-title: Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study publication-title: Lancet Oncol – volume: 67 start-page: 866 year: 2015 end-page: 873 ident: bib49 article-title: Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU–AA–301 publication-title: Eur Urol – volume: 375 start-page: 1437 year: 2010 end-page: 1446 ident: bib23 article-title: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study publication-title: Lancet – volume: 31 start-page: 6 year: 2013 ident: bib50 article-title: Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor publication-title: Proc Am Soc Clin Oncol – volume: 371 start-page: 424 year: 2014 end-page: 433 ident: bib11 article-title: Enzalutamide in metastatic prostate cancer before chemotherapy publication-title: N Engl J Med – volume: 19 start-page: 2973 year: 2013 end-page: 2983 ident: bib18 article-title: Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors publication-title: Clin Cancer Res – volume: 376 start-page: 1147 year: 2010 end-page: 1154 ident: bib7 article-title: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial publication-title: Lancet – volume: 31 start-page: 412 year: 2013 end-page: 419 ident: bib75 article-title: Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial publication-title: J Clin Oncol – volume: 65 start-page: 30 year: 2014 end-page: 36 ident: bib33 article-title: Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone publication-title: Eur Urol – volume: 25 start-page: 657 year: 2014 end-page: 662 ident: bib64 article-title: Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer publication-title: Ann Oncol – volume: 3 start-page: 1020 year: 2013 end-page: 1029 ident: bib65 article-title: A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509 publication-title: Cancer Discov – volume: 66 start-page: 459 year: 2014 end-page: 465 ident: bib38 article-title: Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents publication-title: Eur Urol – volume: 69 start-page: 2912 year: 2009 end-page: 2918 ident: bib61 article-title: Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer publication-title: Cancer Res – volume: 19 start-page: 1335 year: 2013 end-page: 1339 ident: bib22 article-title: Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer publication-title: Clin Cancer Res – volume: 14 start-page: 2763 year: 2008 end-page: 2767 ident: bib67 article-title: Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study publication-title: Clin Cancer Res – volume: 14 start-page: 6302 year: 2008 end-page: 6309 ident: bib76 article-title: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer publication-title: Clin Cancer Res – volume: 109 start-page: 1079 year: 2013 end-page: 1084 ident: bib44 article-title: Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer publication-title: Br J Cancer – volume: 113 start-page: 2478 year: 2008 end-page: 2487 ident: bib57 article-title: Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer publication-title: Cancer – volume: 67 start-page: 673 year: 2014 end-page: 679 ident: bib45 article-title: A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer publication-title: Eur Urol – volume: 155 start-page: 1309 year: 2013 end-page: 1322 ident: bib46 article-title: Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade publication-title: Cell – volume: 24 start-page: 2402 year: 2013 end-page: 2408 ident: bib19 article-title: Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial publication-title: Ann Oncol – volume: 72 start-page: 3457 year: 2012 end-page: 3462 ident: bib72 article-title: Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer publication-title: Cancer Res – ident: bib1 article-title: GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide – volume: 26 start-page: 242 year: 2008 end-page: 245 ident: bib4 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study publication-title: J Clin Oncol – volume: 67 start-page: 795 year: 2014 end-page: 802 ident: bib63 article-title: PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate publication-title: Eur Urol – volume: 26 start-page: 750 year: 2015 end-page: 755 ident: bib70 article-title: Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use publication-title: Ann Oncol – volume: 32 start-page: BA2 year: 2014 ident: bib3 article-title: Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial publication-title: Proc Am Soc Clin Oncol – volume: 6 start-page: 703 year: 2000 end-page: 706 ident: bib47 article-title: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor publication-title: Nat Med – volume: 13 start-page: 983 year: 2012 end-page: 992 ident: bib8 article-title: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study publication-title: Lancet Oncol – volume: 72 start-page: 2176 year: 2012 end-page: 2182 ident: bib21 article-title: Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 publication-title: Cancer Res – volume: 20 start-page: 27 year: 2009 end-page: 33 ident: bib77 article-title: Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience publication-title: Ann Oncol – volume: 71 start-page: 6019 year: 2011 end-page: 6029 ident: bib42 article-title: Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer publication-title: Cancer Res – volume: 50 start-page: 78 year: 2013 end-page: 84 ident: bib34 article-title: Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone publication-title: Eur J Cancer – volume: 24 start-page: 1807 year: 2013 end-page: 1812 ident: bib31 article-title: Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) publication-title: Ann Oncol – volume: 99 start-page: 765 year: 2007 end-page: 776 ident: bib55 article-title: Oral sodium clodronate for nonmetastatic prostate cancer—results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873) publication-title: J Nat Cancer Inst – volume: 33 start-page: 1348 year: 2015 end-page: 1355 ident: bib78 article-title: Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer publication-title: J Clin Oncol – volume: 371 start-page: 1028 year: 2014 end-page: 1038 ident: bib59 article-title: AR–V7 and resistance to enzalutamide and abiraterone in prostate cancer publication-title: N Engl J Med – volume: 31 start-page: 2791 year: 2013 end-page: 2798 ident: bib69 article-title: Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial publication-title: J Clin Oncol – volume: 136 start-page: E760 year: 2015 end-page: E772 ident: bib40 article-title: CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel publication-title: Int J Cancer – volume: 21 start-page: 1273 year: 2014 end-page: 1280 ident: bib66 article-title: Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors publication-title: Clin Cancer Res – volume: 81 start-page: 1297 year: 2013 end-page: 1302 ident: bib25 article-title: Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial publication-title: Urology – volume: 12 start-page: e167 year: 2014 end-page: e172 ident: bib29 article-title: Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment publication-title: Clin Genitourin Cancer – volume: 24 start-page: 3089 year: 2006 end-page: 3094 ident: bib12 article-title: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer publication-title: J Clin Oncol – volume: 28 start-page: 372 year: 2010 end-page: 379 ident: bib53 article-title: Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy publication-title: Magn Reson Imaging – volume: 67 start-page: 482 year: 2015 end-page: 491 ident: bib56 article-title: Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (Zeus) publication-title: Eur Urol – start-page: 1 year: 2013 end-page: 8 ident: bib35 article-title: Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate publication-title: Scand J Urol – volume: 66 start-page: e71 year: 2014 end-page: e72 ident: bib41 article-title: Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies publication-title: Eur Urol – volume: 21 start-page: 1621 year: 2015 end-page: 1627 ident: bib60 article-title: Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate publication-title: Clin Cancer Res – volume: 19 start-page: 1749 year: 2008 end-page: 1753 ident: bib16 article-title: Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa publication-title: Ann Oncol – volume: 115 start-page: 3670 year: 2009 end-page: 3679 ident: bib13 article-title: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer publication-title: Cancer – volume: 66 start-page: 330 year: 2013 end-page: 336 ident: bib68 article-title: Initial biopsy gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study publication-title: Eur Urol – volume: 66 start-page: e71 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib41 article-title: Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies publication-title: Eur Urol – volume: 33 start-page: 1348 year: 2015 ident: 10.1016/S1470-2045(15)70033-1_bib78 article-title: Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2014.55.3487 – volume: 24 start-page: 1802 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib32 article-title: Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide publication-title: Ann Oncol doi: 10.1093/annonc/mdt138 – volume: 12 start-page: 428 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib39 article-title: Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer publication-title: Clin Genitourin Cancer doi: 10.1016/j.clgc.2014.06.007 – volume: 31 start-page: 412 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib75 article-title: Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial publication-title: J Clin Oncol doi: 10.1200/JCO.2012.45.0494 – volume: 376 start-page: 1147 year: 2010 ident: 10.1016/S1470-2045(15)70033-1_bib7 article-title: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial publication-title: Lancet doi: 10.1016/S0140-6736(10)61389-X – volume: 371 start-page: 424 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib11 article-title: Enzalutamide in metastatic prostate cancer before chemotherapy publication-title: N Engl J Med doi: 10.1056/NEJMoa1405095 – volume: 23 start-page: 2943 year: 2012 ident: 10.1016/S1470-2045(15)70033-1_bib27 article-title: Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? publication-title: Ann Oncol doi: 10.1093/annonc/mds119 – volume: 20 start-page: 27 year: 2009 ident: 10.1016/S1470-2045(15)70033-1_bib77 article-title: Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience publication-title: Ann Oncol doi: 10.1093/annonc/mdn544 – volume: 369 start-page: 213 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib15 article-title: Alpha emitter radium-223 and survival in metastatic prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1213755 – volume: 81 start-page: 1297 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib25 article-title: Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial publication-title: Urology doi: 10.1016/j.urology.2013.01.061 – volume: 24 start-page: 2828 year: 2006 ident: 10.1016/S1470-2045(15)70033-1_bib17 article-title: Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.8207 – volume: 62 start-page: 137 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib71 article-title: Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-012-1317-2 – volume: 14 start-page: 6302 year: 2008 ident: 10.1016/S1470-2045(15)70033-1_bib76 article-title: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0872 – volume: 74 start-page: 1544 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib30 article-title: A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer publication-title: Prostate doi: 10.1002/pros.22872 – volume: 28 start-page: 372 year: 2010 ident: 10.1016/S1470-2045(15)70033-1_bib53 article-title: Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy publication-title: Magn Reson Imaging doi: 10.1016/j.mri.2009.12.008 – volume: 69 start-page: 2912 year: 2009 ident: 10.1016/S1470-2045(15)70033-1_bib61 article-title: Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-3667 – volume: 367 start-page: 1187 year: 2012 ident: 10.1016/S1470-2045(15)70033-1_bib10 article-title: Increased survival with enzalutamide in prostate cancer after chemotherapy publication-title: N Engl J Med doi: 10.1056/NEJMoa1207506 – volume: 13 start-page: 983 year: 2012 ident: 10.1016/S1470-2045(15)70033-1_bib8 article-title: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70379-0 – ident: 10.1016/S1470-2045(15)70033-1_bib1 – volume: 67 start-page: 673 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib45 article-title: A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2014.10.004 – volume: 65 start-page: 30 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib33 article-title: Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone publication-title: Eur Urol doi: 10.1016/j.eururo.2013.06.042 – volume: 31 start-page: 6 issue: suppl year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib50 article-title: Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor publication-title: Proc Am Soc Clin Oncol doi: 10.1200/jco.2013.31.6_suppl.6 – volume: 113 start-page: 2478 year: 2008 ident: 10.1016/S1470-2045(15)70033-1_bib57 article-title: Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer publication-title: Cancer doi: 10.1002/cncr.23864 – volume: 371 start-page: 1028 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib59 article-title: AR–V7 and resistance to enzalutamide and abiraterone in prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1315815 – volume: 136 start-page: E760 year: 2015 ident: 10.1016/S1470-2045(15)70033-1_bib40 article-title: CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel publication-title: Int J Cancer doi: 10.1002/ijc.29231 – volume: 25 start-page: 657 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib64 article-title: Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdt581 – volume: 3 start-page: 1020 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib65 article-title: A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-13-0226 – volume: 375 start-page: 1437 year: 2010 ident: 10.1016/S1470-2045(15)70033-1_bib23 article-title: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study publication-title: Lancet doi: 10.1016/S0140-6736(10)60172-9 – volume: 97 start-page: 541 year: 1943 ident: 10.1016/S1470-2045(15)70033-1_bib2 article-title: Endocrine control of prostate cancer publication-title: Science doi: 10.1126/science.97.2529.541 – volume: 368 start-page: 138 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib9 article-title: Abiraterone in metastatic prostate cancer without previous chemotherapy publication-title: N Engl J Med doi: 10.1056/NEJMoa1209096 – volume: 72 start-page: 3457 year: 2012 ident: 10.1016/S1470-2045(15)70033-1_bib72 article-title: Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-3892 – volume: 24 start-page: 2402 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib19 article-title: Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial publication-title: Ann Oncol doi: 10.1093/annonc/mdt194 – volume: 19 start-page: 1335 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib22 article-title: Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-2910 – volume: 71 start-page: 6019 year: 2011 ident: 10.1016/S1470-2045(15)70033-1_bib42 article-title: Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-1417 – volume: 15 start-page: 723 year: 2009 ident: 10.1016/S1470-2045(15)70033-1_bib20 article-title: Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0596 – volume: 67 start-page: 866 year: 2015 ident: 10.1016/S1470-2045(15)70033-1_bib49 article-title: Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU–AA–301 publication-title: Eur Urol doi: 10.1016/j.eururo.2014.06.042 – volume: 379 start-page: 39 year: 2012 ident: 10.1016/S1470-2045(15)70033-1_bib52 article-title: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(11)61226-9 – volume: 99 start-page: 765 year: 2007 ident: 10.1016/S1470-2045(15)70033-1_bib55 article-title: Oral sodium clodronate for nonmetastatic prostate cancer—results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873) publication-title: J Nat Cancer Inst doi: 10.1093/jnci/djk178 – volume: 31 start-page: 2791 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib69 article-title: Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2012.45.4595 – volume: 3 start-page: 1030 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib73 article-title: An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-13-0142 – volume: 24 start-page: 3089 year: 2006 ident: 10.1016/S1470-2045(15)70033-1_bib12 article-title: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.5252 – volume: 15 start-page: 700 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib26 article-title: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70189-5 – volume: 67 start-page: 482 year: 2015 ident: 10.1016/S1470-2045(15)70033-1_bib56 article-title: Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (Zeus) publication-title: Eur Urol doi: 10.1016/j.eururo.2014.02.014 – volume: 26 start-page: 750 year: 2015 ident: 10.1016/S1470-2045(15)70033-1_bib70 article-title: Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use publication-title: Ann Oncol doi: 10.1093/annonc/mdu587 – volume: 16 start-page: 152 year: 2015 ident: 10.1016/S1470-2045(15)70033-1_bib24 article-title: Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71205-7 – volume: 363 start-page: 411 year: 2010 ident: 10.1016/S1470-2045(15)70033-1_bib14 article-title: Sipuleucel-T immunotherapy for castration-resistant prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1001294 – volume: 67 start-page: 23 year: 2015 ident: 10.1016/S1470-2045(15)70033-1_bib37 article-title: Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients publication-title: Eur Urol doi: 10.1016/j.eururo.2014.06.045 – start-page: 1 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib35 article-title: Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate publication-title: Scand J Urol – volume: 155 start-page: 1309 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib46 article-title: Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade publication-title: Cell doi: 10.1016/j.cell.2013.11.012 – volume: 21 start-page: 1621 year: 2015 ident: 10.1016/S1470-2045(15)70033-1_bib60 article-title: Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1961 – volume: 50 start-page: 78 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib34 article-title: Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.08.020 – volume: 32 start-page: BA2 issue: suppl 1 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib3 article-title: Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial publication-title: Proc Am Soc Clin Oncol doi: 10.1200/jco.2014.32.18_suppl.lba2 – volume: 115 start-page: 744 year: 2015 ident: 10.1016/S1470-2045(15)70033-1_bib43 article-title: Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer publication-title: BJU Int doi: 10.1111/bju.12845 – volume: 26 start-page: 242 year: 2008 ident: 10.1016/S1470-2045(15)70033-1_bib4 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study publication-title: J Clin Oncol doi: 10.1200/JCO.2007.12.4008 – volume: 19 start-page: 2973 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib18 article-title: Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-3146 – volume: 72 start-page: 2176 year: 2012 ident: 10.1016/S1470-2045(15)70033-1_bib21 article-title: Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-3980 – volume: 66 start-page: 646 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib28 article-title: The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2014.01.018 – volume: 21 start-page: 1273 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib66 article-title: Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1220 – volume: 6 start-page: 254ra125 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib48 article-title: Tumor clone dynamics in lethal prostate cancer publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3009448 – volume: 66 start-page: 459 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib38 article-title: Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents publication-title: Eur Urol doi: 10.1016/j.eururo.2013.11.044 – volume: 12 start-page: e167 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib29 article-title: Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment publication-title: Clin Genitourin Cancer doi: 10.1016/j.clgc.2014.03.010 – volume: 120 start-page: 968 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib36 article-title: Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment publication-title: Cancer doi: 10.1002/cncr.28518 – volume: 351 start-page: 1513 year: 2004 ident: 10.1016/S1470-2045(15)70033-1_bib5 article-title: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa041318 – volume: 23 start-page: 2918 year: 2005 ident: 10.1016/S1470-2045(15)70033-1_bib54 article-title: Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.01.529 – volume: 24 start-page: 1807 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib31 article-title: Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) publication-title: Ann Oncol doi: 10.1093/annonc/mdt136 – volume: 109 start-page: 1079 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib44 article-title: Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer publication-title: Br J Cancer doi: 10.1038/bjc.2013.446 – volume: 16 start-page: 187 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib58 article-title: Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/pcan.2013.2 – volume: 19 start-page: 1749 year: 2008 ident: 10.1016/S1470-2045(15)70033-1_bib16 article-title: Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa publication-title: Ann Oncol doi: 10.1093/annonc/mdn288 – volume: 14 start-page: 2763 year: 2008 ident: 10.1016/S1470-2045(15)70033-1_bib67 article-title: Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-0944 – volume: 65 start-page: 1180 year: 2011 ident: 10.1016/S1470-2045(15)70033-1_bib51 article-title: Characterising the castration-resistant prostate cancer population: a systematic review publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2011.02799.x – volume: 26 start-page: 1148 year: 2008 ident: 10.1016/S1470-2045(15)70033-1_bib74 article-title: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group publication-title: J Clin Oncol doi: 10.1200/JCO.2007.12.4487 – volume: 5 start-page: 5548 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib62 article-title: ERG induces taxane resistance in castration-resistant prostate cancer publication-title: Nat Commun doi: 10.1038/ncomms6548 – volume: 66 start-page: 330 year: 2013 ident: 10.1016/S1470-2045(15)70033-1_bib68 article-title: Initial biopsy gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study publication-title: Eur Urol doi: 10.1016/j.eururo.2013.08.007 – volume: 351 start-page: 1502 year: 2004 ident: 10.1016/S1470-2045(15)70033-1_bib6 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa040720 – volume: 6 start-page: 703 year: 2000 ident: 10.1016/S1470-2045(15)70033-1_bib47 article-title: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor publication-title: Nat Med doi: 10.1038/76287 – volume: 67 start-page: 795 year: 2014 ident: 10.1016/S1470-2045(15)70033-1_bib63 article-title: PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate publication-title: Eur Urol doi: 10.1016/j.eururo.2014.10.027 – volume: 115 start-page: 3670 year: 2009 ident: 10.1016/S1470-2045(15)70033-1_bib13 article-title: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer publication-title: Cancer doi: 10.1002/cncr.24429 |
| SSID | ssj0017105 |
| Score | 2.5133848 |
| SecondaryResourceType | review_article |
| Snippet | Until 2010, docetaxel was the only agent with proven survival benefit for castration-resistant prostate cancer. The development of cabazitaxel, abiraterone... Summary Until 2010, docetaxel was the only agent with proven survival benefit for castration-resistant prostate cancer. The development of cabazitaxel,... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e279 |
| SubjectTerms | Abiraterone Acetate Androgens Androstenes - therapeutic use Antigens Benzamides Biomarkers Biopsy Cancer therapies Clinical trials Docetaxel Hematology, Oncology and Palliative Medicine Humans Male Metastasis Mortality Mutation Neurotoxicity Nitriles Pain Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - therapeutic use Prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - epidemiology Prostatic Neoplasms, Castration-Resistant - pathology Quality of life Radioisotopes - therapeutic use Radium - therapeutic use Response rates Taxoids - therapeutic use Tissue Extracts - therapeutic use Treatment Outcome |
| Title | Sequencing of agents in castration-resistant prostate cancer |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204515700331 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204515700331 https://dx.doi.org/10.1016/S1470-2045(15)70033-1 https://www.ncbi.nlm.nih.gov/pubmed/26065613 https://www.proquest.com/docview/1683584898 https://www.proquest.com/docview/1703709042 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS-QwFD7oCOKL7Hrb0Vmp4IM-RJsmTVJYWFZRRFDEC8xbyCQpCNKZteP_96RN64u3lz60_Vp6mnPyneRcAPazpsiVUYTxzBAuspJMnCmIUJZJnk-U8SFR-OpaXDzwy3E-jgtudQyr7GxiY6jd1IY18mMqkCsorgr1d_afhK5RYXc1ttBYhKVQuiyMajnuHS4q2xBGymVKQtn1twye47v-5AHND2XT0ox-NDd9xD2bOej8B6xG8pj8a__2T1jw1RosX8Xt8XX4c9cGRuN0lEzLxIS0qTp5rBJruvK4BN3rQBmreTILCR9INfEq_vnnDXg4P7s_vSCxPQKxKOA5sVJNqHeZUyVz1BbMGfxiqywaDmEKblF_M4E3FK6pRoyy85KV3KSOIU0r2SYMqmnlf0FieUkZdSa1HjXaIFjhc2laojvFTCaGwDvBaBtrh4cWFk-6DxIL8tRBnprmupGnpkM46mGztnjGVwDRSV13maFoyzSa96-A8j2gr6NG1prqOtNpiw5gmjdQRKoeGUlHSya-89JRNzD023v6cTqEvf4y6mzYiDGVn77gPWhmZVqgvRzCVjugevmgfymCU7f9-cN3YAWpW94GrY1gMH9-8b-RHs0nu40O4FGd0l1YOjm7vrl9BRHhBp0 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxEB61RWq5IB4tBAJdJCq1B5P1Y71eCYRQaZXSppe2Um-uY3slJLQJ3USIP8VvZOx99EIpl16z-9nRZGb8TTwPgHcsNrkyinDBDBGSlWTqTEGksjwX2VQZHwqFJ6dyfCG-XmaXK_C7q4UJaZWdT4yO2s1s-I98RCVyBSVUoT7Nf5AwNSrcrnYjNBq1OPa_fmLIVn88-oK_7w5jhwfn-2PSThUgFr_XgthcTal3zKmSO2oL7gzNqVUW7U2aQlhUeybxhcLFJr64pc95KUzqOLKbkuO6q_BAcDTNUJm-36eU4DIxZZKKPCWhzftNxdDorP9wl2Z7eRyhRm87C2_juvHMO3wMj1qymnxutOsJrPjqKaxP2uv4Z_DhrEnExuMvmZWJCWVadfKtSqzp2vESDOcDRa0WyTwUmCC1xaeoadebcHEvgtuCtWpW-ReQWFFSTp1JrUcPYhCscF2alhi-ccPkAEQnGG3bXuVhZMZ33SelBXnqIE9NMx3lqekA3vewedOs4y6A7KSuu0pU9J0aj5O7gPnfgL5uPUCtqa6ZTht0ANMsQhGpemRLchry8j-bDjvF0Df79HYxgLf9Y_QR4eLHVH62xHfQredpgf55AM8bherlg_GsDEHky38vvg0b4_PJiT45Oj1-BQ-RNmZNwtwQ1hbXS_8aqdli-ibaQwJX922AfwAUFUAD |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1baxQxFD7UFoovoq2X1WpHqKAPcSeXSTKgiLQuvSPUQt_SbJIBQWbXzhbxr_nrPMlc-mJtX_q6M1-ynD3n5DubcwHYYqnJldWEC2aJkKwiU29LIrXjShRTbUMsFD46lrunYv-sOFuCP30tTEyr7H1ictR-5uJ_5GMqkStooUs9rrq0iK87k0_znyROkIo3rf04jVZFDsLvXxi-NR_3dvC3fsPY5Mu37V3STRggDr_jgjilpzR45nXFPXUl95Yq6rRD25O2FA5NgEl8ofSpoS9uHxSvhM09R6ZTcVz3HqwornS0Mb09pJfgMil9kgqVk9jy_ap6aHwyfPiWFu9UGqdGrzsXr-O96fybPIQHHXHNPrea9giWQr0Gq0fd1fw6fDhpk7LxKMxmVWZjyVaTfa8zZ_vWvARD-0hX60U2j8UmSHPxKWrdxWM4vRPBPYHlelaHZ5A5UVFOvc1dQG9iEaxxXZpXGMpxy-QIRC8Y47q-5XF8xg8zJKhFeZooT0MLk-Rp6AjeD7B527jjJoDspW76qlT0owaPlpuA6l_A0HTeoDHUNMzkLTqCaZGgiNQDsiM8LZG5zaYbvWKYq30GGxnB6-Ex-ot4CWTrMLvEd9DFq7xEXz2Cp61CDfLB2FbGgPL5_xffhFU0PXO4d3zwAu4jgyza3LkNWF5cXIaXyNIW01fJHDI4v2v7-wuFQEQ5 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sequencing+of+agents+in+castration-resistant+prostate+cancer&rft.jtitle=The+lancet+oncology&rft.au=Lorente%2C+David%2C+MD&rft.au=Mateo%2C+Joaquin%2C+MD&rft.au=Perez-Lopez%2C+Raquel%2C+MD&rft.au=de+Bono%2C+Johann+S%2C+Prof&rft.date=2015-06-01&rft.issn=1470-2045&rft.volume=16&rft.issue=6&rft.spage=e279&rft.epage=e292&rft_id=info:doi/10.1016%2FS1470-2045%2815%2970033-1&rft.externalDBID=ECK1-s2.0-S1470204515700331&rft.externalDocID=1_s2_0_S1470204515700331 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204515X71798%2Fcov150h.gif |